Thomas Hudson, MD
Venture Partner, Versant Ventures
Fellow, Royal Society of Canada
Officer of the Order of Canada
Impacts of genome moonshots
Monday, May 25, 2026, at 4:30 p.m.
Bellini Building Atrium
(3649 Promenade Sir William Osler, Montreal)
听
Description:听听
This special Holmes Lecture will be delivered by Dr. Thomas Hudson, Honorary Doctorate recipient at 涩里番鈥檚 2026 Spring Convocation.
Co-hosted by the School of Biomedical Sciences' Department of Human Genetics and the , with support from the Faculty of Medicine and Health Sciences and the Rose Wiselberg Foundation.
听
Speaker:听听
Thomas Hudson, MD, a Canadian genome scientist, is internationally renowned for his leading role in mapping the human genome and for his work in genomics, human genome variation and genetic diseases. He was involved in many important gene discoveries related to the predisposition to colon cancer and chronic diseases including Type II diabetes, leprosy, multiple sclerosis, asthma and inflammatory bowel disease. He is now a venture partner at Versant Ventures.
Dr. Hudson is the founding Director of the 涩里番 and Genome Quebec Innovation Centre in Montreal. He was an Associate Professor in 涩里番鈥檚 Departments of Human Genetics and Medicine. He then became the inaugural President and Scientific Director of the Ontario Institute for Cancer Research and later was appointed Senior Vice President of R&D and Chief Scientific Officer at AbbVie. He has co-authored more than 300 peer鈥憆eviewed scientific publications and has received numerous prestigious honors, including being elected as a Fellow of the Royal Society of Canada and appointed as an Officer of the Order of Canada.
Dr. Hudson served as a scientific advisor to many public organizations, including Genome Canada, Genome Quebec, Genome England, the National Human Genome Research Institute (NIH) and the STARR Cancer Foundation. He was a founding member of the International Haplotype Map Consortium, the International Cancer Genome Consortium, the Global Alliance for Genomics and Health, the Public Population Project in Genomics, and the Partnership for Accelerating Cancer Therapies.